Plain-English translation of NCT07468630 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a new medication called tolecizumab, when combined with immunotherapy and chemotherapy, can help treat locally advanced colon cancer more effectively. You would receive four rounds of treatment before surgery. The goal is to see if this combination approach shrinks the tumor more completely than the standard two-drug treatment alone.
Standard immunotherapy and chemotherapy help many patients with advanced colon cancer, but not everyone responds well. Researchers believe that this medication may boost the immune system's ability to fight the cancer when combined with existing treatments, potentially improving outcomes for patients who might not respond to treatment alone.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of two groups: one receiving the new medication plus two standard drugs, or one receiving just the two standard drugs. You would receive four cycles of treatment over about 12 weeks, with intravenous infusions every three weeks and daily oral medication. After treatment, you would have surgery to remove the tumor, then be followed for safety checks for 90 days and survival monitoring for up to three years. All study drugs and related tests are provided free of charge.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China